Literature DB >> 23177280

Hepatitis C viral kinetics: the past, present, and future.

Anushree Chatterjee1, Patrick F Smith, Alan S Perelson.   

Abstract

Mathematical modeling of hepatitis C viral kinetics has been an important tool in understanding hepatitis C virus (HCV) infection dynamics and in estimating crucial in vivo parameters characterizing the effectiveness of HCV therapy. Because of the introduction of direct-acting antiviral agents, there is a need to extend previous models so as to understand, characterize, and compare various new HCV treatment regimens. Here we review recent modeling efforts in this direction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23177280      PMCID： PMC3584572          DOI： 10.1016/j.cld.2012.09.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  62 in total

1.  IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.

Authors:  Martin Lagging; Ana I Romero; Johan Westin; Gunnar Norkrans; Amar P Dhillon; Jean-Michel Pawlotsky; Stefan Zeuzem; Michael von Wagner; Francesco Negro; Solko W Schalm; Bart L Haagmans; Carlo Ferrari; Gabriele Missale; Avidan U Neumann; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

2.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

3.  In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Authors:  Chao Lin; Cynthia A Gates; B Govinda Rao; Debra L Brennan; John R Fulghum; Yu-Ping Luong; J Daniel Frantz; Kai Lin; Sue Ma; Yun-Yi Wei; Robert B Perni; Ann D Kwong
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

4.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

Review 5.  Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 6.  Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.

Authors:  Libin Rong; Alan S Perelson
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

7.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

8.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Authors:  Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E Sentjens; José L Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

9.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Abdelhakim Ahmed-Belkacem; Nazim Ahnou; Laetitia Barbotte; Czeslaw Wychowski; Coralie Pallier; Rozenn Brillet; Ralf-Torsten Pohl; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2009-12-04       Impact factor: 22.682
View more
  10 in total

1.  Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.

Authors:  Eric L Haseltine; Holly Kimko; Haobin Luo; John Tolsma; Doug J Bartels; Tara L Kieffer; Varun Garg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-20       Impact factor: 2.745

2.  Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.

Authors:  Libin Rong; Alan S Perelson
Journal:  Math Biosci       Date:  2013-05-16       Impact factor: 2.144

3.  Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  ACS Infect Dis       Date:  2015-08-11       Impact factor: 5.084

4.  Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.

Authors:  Thomas R Aunins; Katherine A Marsh; Gitanjali Subramanya; Susan L Uprichard; Alan S Perelson; Anushree Chatterjee
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

5.  Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.

Authors:  Frederik Graw; Ashwin Balagopal; Abraham J Kandathil; Stuart C Ray; David L Thomas; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-11-13       Impact factor: 4.475

6.  Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection.

Authors:  Philipp Solbach; Sandra Westhaus; Maximilian Deest; Eva Herrmann; Thomas Berg; Michael P Manns; Sandra Ciesek; Christoph Sarrazin; Thomas von Hahn
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-03-14

7.  Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.

Authors:  Daisuke Endo; Kenichi Satoh; Noritomo Shimada; Atsushi Hokari; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2017-04-07       Impact factor: 5.742

Review 8.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

9.  Assessing Uncertainty in A2 Respiratory Syncytial Virus Viral Dynamics.

Authors:  Gilberto González-Parra; Hana M Dobrovolny
Journal:  Comput Math Methods Med       Date:  2015-09-14       Impact factor: 2.238

10.  Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.

Authors:  A Ajlan; A Al-Jedai; H Elsiesy; D Alkortas; W Al-Hamoudi; R Alarieh; M Al-Sebayel; D Broering; F Aba Alkhail
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.